INmune Bio, Inc. (NASDAQ:INMB) Given Average Rating of “Reduce” by Brokerages

INmune Bio, Inc. (NASDAQ:INMB) has received a consensus recommendation of “Reduce” from the five analysts that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $8.00.

Separately, Wall Street Zen lowered INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday.

Hedge Funds Weigh In On INmune Bio

Large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. increased its stake in INmune Bio by 269.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 56,477 shares of the company’s stock worth $88,000 after buying an additional 41,173 shares during the period. Squarepoint Ops LLC acquired a new stake in INmune Bio during the third quarter worth approximately $30,000. Cary Street Partners Financial LLC purchased a new stake in INmune Bio in the third quarter valued at $29,000. Vanguard Group Inc. boosted its position in shares of INmune Bio by 3.4% in the 3rd quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock valued at $1,814,000 after purchasing an additional 28,541 shares during the period. Finally, Westside Investment Management Inc. boosted its holdings in shares of INmune Bio by 384.0% in the third quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock valued at $214,000 after acquiring an additional 82,075 shares during the period. 12.72% of the stock is currently owned by institutional investors and hedge funds.

INmune Bio Price Performance

INmune Bio stock opened at $1.60 on Wednesday. The business has a 50 day simple moving average of $1.70 and a 200-day simple moving average of $1.90. The stock has a market capitalization of $42.53 million, a PE ratio of -0.75 and a beta of 0.72. INmune Bio has a 12 month low of $1.38 and a 12 month high of $11.64.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.